InnovoTEX

Innovo Tex

Biotechnology, 3800 N Lamar BLVD, Austin, Texas, 78756, United States, 1-10 Employees

innovotexinc.com

  • LinkedIn

Who is INNOVOTEX

Developing the next generation of therapeutic innovation. InnovoTEX is an oncology therapeutic company developing its proprietary TEX Core platform which utilizes a clinically validated t...

Read More

map
  • 3800 N Lamar BLVD, Austin, Texas, 78756, United States Headquarters: 3800 N Lamar BLVD, Austin, Texas, 78756, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $50 Million to $100 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INNOVOTEX

InnovoTEX Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding InnovoTEX

Answer: InnovoTEX's headquarters are located at 3800 N Lamar BLVD, Austin, Texas, 78756, United States

Answer: InnovoTEX's official website is https://innovotexinc.com

Answer: InnovoTEX's revenue is $50 Million to $100 Million

Answer: InnovoTEX's SIC: 8731

Answer: InnovoTEX's NAICS: 541715

Answer: InnovoTEX has 1-10 employees

Answer: InnovoTEX is in Biotechnology

Answer: InnovoTEX contact info: Phone number: Website: https://innovotexinc.com

Answer: Developing the next generation of therapeutic innovation. InnovoTEX is an oncology therapeutic company developing its proprietary TEX Core platform which utilizes a clinically validated texaphyrin core to uniquely design novel assets. We identified a lead clinical candidate, OxaliTEX, that activates ribosomal biosynthesis stress to induce wt-p53 and circumvent platinum resistance in wt-p53 refractory cancers, including ovarian cancer. Secondary candidates are in early development for multiple solid tumor indications. Our exclusive IP portfolio is licensed from UT Austin and MD Anderson Cancer Center, which supports our strong collaboration with each institution for continued development work. We are in early conversations with large pharma for potential milestone partnerships that could result in an early exit within 2-5 years.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access